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The endocytic Ashwell-Morell receptor (AMR) of hepatocytes de-
tects pathogen remodeling of host glycoproteins by neuramin-
idase in the bloodstream and mitigates the lethal coagulopathy of
sepsis. We have investigated the mechanism of host protection by
the AMR during the onset of sepsis and in response to the
desialylation of blood glycoproteins by the NanA neuraminidase
of Streptococcus pneumoniae. We !nd that the AMR selects among
potential glycoprotein ligands unmasked by microbial neuramini-
dase activity in pneumococcal sepsis to eliminate from blood circula-
tion host factors that contribute to coagulation and thrombosis.
This protection is attributable in large part to the rapid induc-
tion of a moderate thrombocytopenia by the AMR. We further
show that neuraminidase activity in the blood can be manipu-
lated to induce the clearance of AMR ligands including platelets,
thereby preactivating a protective response in pneumococcal
sepsis that moderates the severity of disseminated intravascular
coagulation and enables host survival.
Pathogens in the host bloodstream often induce a hyperactivecoagulation cascade that can progress to disseminated intra-
vascular coagulation with severe thrombosis, organ failure, and
death (1–3). With current limited understanding of pathogen–host
interactions, sepsis remains a debilitating and deadly syndrome
with few treatment options (4, 5). An unexpected protective
host response that reduces coagulopathy during sepsis caused
by Streptococcus pneumoniae (SPN) was recently discovered in
studies of the endocytic Ashwell-Morell receptor (AMR) (6, 7).
Host protection by the AMR is linked to the hydrolysis of sialic
acids from blood glycoproteins by the neuraminidase A (NanA)
of SPN. Sialic acids are posttranslational glycan modi!cations
often attached to underlying galactose on many cell surface and
secreted glycoproteins (8, 9).
Neuraminidases (aka sialidases) produced by microbial path-
ogens hydrolyze sialic acids on glycoproteins to establish infec-
tion and facilitate host colonization (10). For example, NanA
remodels mucosal cell surface glycoproteins to promote bacterial
colonization of the upper respiratory tract (11, 12) and con-
tributes to pulmonary in"ammation along with the development
of SPN pneumonia (13, 14). However, the host has adapted to
counteract the pathological effects of this SPN virulence factor
by the clearance from blood circulation of host factors bearing
AMR ligands that have been unmasked by NanA desialylation.
In this study we have identi!ed multiple blood components
that are removed from circulation by the AMR and have de-
termined which of these are primarily responsible for diminish-
ing the lethal coagulopathy of SPN sepsis. We have further used
this information to develop and assess a prophylactic approach
that preactivates AMR function in the early phases of sepsis to
reduce the severity and lethality of the ensuing coagulopathy.
Results
Intravenous (i.v.) administration of three different puri!ed mi-
crobial neuraminidases each effectively desialylated platelets and
induced a rapid moderate thrombocytopenia in mice (Fig. 1 A
and B and Fig. S1). At saturating doses of neuraminidase activity,
circulating platelet levels were reduced by 70% within 2 h, with
thrombocytopenia persisting for up to 72 h, before platelets
rebounded to normal abundance coincident with restoration of cell
surface sialic acids. Neuraminidase-induced unmasking of galac-
tose was detected on multiple blood glycoproteins, whereas no
signi!cant alterations occurred in blood chemistry or in the abun-
dance of blood cells and various in"ammation markers (Figs. S2
and S3 and Table S1). In addition, neuraminidase did not alter
the expression of multiple glycoproteins and receptors residing
at the platelet plasma membrane (Fig. S4). All microbial neu-
raminidases analyzed produced similar outcomes in these and
subsequent experiments detailed below.
Bleeding times were rapidly increased within 2 h of i.v. ad-
ministration of neuraminidase and continued to be elevated
for up to 96 h (Fig. 1C). In animals lacking the AMR, i.v. neur-
aminidase treatment desialylated circulating platelets, whereas no
change occurred in platelet levels, and bleeding times remained
normal (Fig. 1 D and E). Gp1b! is a highly sialylated platelet
glycoprotein that has been reported to facilitate platelet in-
gestion by the AMR in hepatocyte culture (15). Upon exposure
to neuraminidase, platelets lacking Gp1b! exhibited fewer un-
masked galactose termini on their cell surface glycoproteins
compared with WT platelets (Fig. 1F). Adoptive transfer studies
revealed that the rate of neuraminidase-induced platelet clear-
ance by the AMR was markedly reduced in the absence of Gp1b!
(Fig. 1G); nevertheless, circulating platelets were reduced by 70%
after 24 h (Fig. 1H). Therefore, Gp1b! is required to achieve
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a rapid rate of AMR-dependent platelet clearance after neur-
aminidase treatment, whereas platelet glycoproteins other than
Gp1b! can also serve as AMR ligands.
Intravenous neuraminidase treatment was investigated as a
means to reduce coagulopathy and enhance host survival during
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Fig. 1. Intravenous neuraminidase treatment in
platelet desialylation and turnover, bleeding
time increases, and Gp1b!-dependent platelet
clearance involving AMR function. (A) Circulat-
ing platelet abundance, (B) Erythrina cristagalli
lectin (ECA) and Ricinus communis-1 agglutinin
(RCA-I) lectin binding at the platelet surface, and
(C) bleeding times in response to a single i.v.
administration of neuraminidase (NA) or PBS in
WT mice. (D) Platelet abundance and (E) bleed-
ing times among mice identically treated but
lacking either Asgr1 or Asgr2 components of the
AMR. (F) Gp1b! de"ciency and neuraminidase-
induced desialylation among platelets of indi-
cated genotypes. (G) Circulating platelet clearance
after platelet isolation, labeling, and transfer among
mice of indicated donor and recipient genotypes. (H)
Platelet abundance in WT or GP1b!-de"cient mice
24 h after i.v. neuraminidase or PBS treatment.
Antibody to CD41 was used to detect and quantify
platelets in whole blood. In these studies mice
were treated with either 5 U/kg of Arthrobacter
urefaciens neuraminidase or PBS control. Studies
included between 12 and 24 age-matched adult
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Fig. 2. Effects of intravenous neuraminidase treatment on coagulopathy, organ damage, and host survival in SPN sepsis. (A) WT mice were infected by i.p. injection
of 104 cfu of SPN isolate D39, and survival was followed over time among cohorts receiving either AUS neuraminidase (NA) (5 U/kg) or PBS at 8 h after infection. More
than 40 mice receiving each treatment were analyzed from multiple independent experiments. (B) Representative macroscopic views of liver and spleen 48 h
after SPN infection. (C) Serum levels of alanine aminotransferase activity. (D) Histopathological analyses of liver and spleen tissue 48 h after infection exhibited "brin
thrombi and empty vessels (open arrows) indicative of thromboembolic occlusions. Functioning blood vessels containing red blood cells are also denoted (closed
arrows). Pyknotic bodies indicating cell death aremarked (asterisks). Fibrin clots, pyknotic bodies, and splenic hemorrhagewere quanti"ed. Studies in B–D compared
12–24 age-matched adult mice of indicated genotypes. ***P < 0.001.
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sham treatment succumbed as expected. In contrast, half of the
animals receiving a single treatment of i.v. neuraminidase sur-
vived (Fig. 2A). Neuraminidase treatment did not modify basic
blood chemistry parameters during sepsis (Table S2). Host
protection conferred by neuraminidase was closely associated
with reduced histopathological evidence of injury to liver and
spleen tissues, lower serum alanine aminotransferase levels (a
marker of hepatocyte injury), and signi!cant reductions in the
frequency of !brin clots, thromboembolic occlusions, hepatocyte
pyknosis, and splenic hemorrhage (Fig. 2 B–D). The timing of
neuraminidase administration after post-i.p. SPN infection was
important in achieving a therapeutic response (Fig. S5).
The role of the AMR in host protection induced by neur-
aminidase was investigated among mice lacking the Asgr1 or
Asgr2 component of the AMR. Both Asgr1 and Asgr2 were es-
sential for the therapeutic effect of i.v. neuraminidase adminis-
tration. At identical and lethal SPN challenge doses, neuraminidase
treatment of animals lacking either Asgr1 or Asgr2 failed to
mitigate disease, and all succumbed to sepsis, whereas at the
same time !50% of WT cohorts that received neuramini-
dase survived (Fig. 3A). Neuraminidase treatment of AMR-
de!cient mice did not alter various blood chemistry components
compared with WT cohorts (Table S2). In contrast, alanine
aminotransferase levels in the sera were markedly elevated
in AMR de!ciency, beyond that of WT counterparts, and
remained signi!cantly higher after neuraminidase treatment
(Fig. 3B). Liver and splenic tissue damage in AMR de!ciency
were only moderately improved by neuraminidase treatment,
judged by frequencies of !brin clots, liver cell death, and
splenic hemorrhage compared with WT animals (Fig. 3 C and
D). The AMR is therefore required for host protection induced
by i.v. neuraminidase treatment. This protection is associated
with the clearance from circulation of desialylated blood
components including platelets that would otherwise par-
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Fig. 3. AMR function in host protection after neuraminidase treatment during SPN sepsis. (A) Survival among cohorts of mice lacking either the Asgr1 or Asgr2
component of the AMR in the presence or absence of neuraminidase (NA) or PBS delivered by i.v. injection 8 h after i.p. injection of SPN isolate D39 (104 cfu). Each
cohort of mice received either AUS neuraminidase (5 U/kg) or PBS at 8 h after infection. More than 40 mice of each genotype receiving the indicated treatments
from multiple independent experiments were analyzed. (B) Serum levels of alanine aminotransferase activity at 48 h. (C) Representative macroscopic views of the
liver and spleen 48 h after SPN infection. (D) Histopathological analyses of liver and spleen tissue 48 h after infection indicated "brin deposition and empty blood
vessels (open arrows). Pyknotic bodies indicating cell death are marked (asterisks). Fibrin clots, pyknotic bodies, and splenic hemorrhage were quanti"ed. At least
12 age-matched mice of each genotype were analyzed in B–D from multiple independent experiments. ***P < 0.001, **P < 0.01, *P < 0.05.











The therapeutic impact of inducing a moderate thrombocyto-
penia was tested using an antibody-mediated (AMR-independent)
platelet elimination strategy. Intravenous administration of
antibody to the platelet-selective integrin!2" (CD41) rapidly
induced a moderate thrombocytopenia and increased bleeding
times in the absence of platelet desialylation, with a response
closely paralleling neuraminidase treatment (Fig. 4 A–D). No
changes in basic blood chemistry were observed after i.v. ad-
ministration of anti-CD41 or IgG (Table S3). Analyses of liver
and spleen tissues revealed that anti-CD41 treatment reduced
vascular occlusions, !brin clots, liver cell death, splenic hemor-
rhage, and alanine aminotransferase levels (Fig. 4 E and F).
Platelet reduction by anti-CD41 treatment further improved sur-
vival frequencies at SPN challenge doses that killed all cohorts
receiving the IgG sham treatment (Fig. 4G). As predicted, anti-
CD41 antibody treatment of either WT or AMR-de!cient mice
produced similar results. These !ndings indicate that the intrinsic
host protection provided by the AMR after i.v. neuraminidase
administration is primarily achieved by the rapid induction of
a moderate thrombocytopenia.
Comparing treatments and outcomes indicated that neur-
aminidase activation of the AMR achieved a somewhat greater
protective measure than did anti-CD41 antibody. We found
that i.v. neuraminidase treatment resulted in additional changes
that primarily serve to lessen thrombosis. Neuraminidase increased
activated partial thromboplastin time (aPTT)—a critical co-
agulation parameter, in both mice and human plasma (Fig. 5 A
and B). The same anticoagulation effect was observed in AMR
de!ciency (Fig. 5C). No change from normal coagulation times
occurred after anti-CD41 antibody treatment (Fig. 5D). Indi-
vidual blood coagulation factor analyses after neuraminidase
treatment revealed signi!cant decreases in the abundance and
activity of prothrombotic components, including von Willebrand
factor and factors II, V, VIII, X, and XI (Fig. 6). These glyco-
proteins contribute to aPTT, and their decreased abundance and
activity explain the increase in coagulation time. Decreases were
also observed in antithrombotic components antithrombin and
!2-antiplasmin, but they were of minor impact by comparison
and would not overcome the induction of a hypocoagulative state
caused by the combined reductions measured in prothrombotic
factors. Other coagulation factors were unchanged by neuramini-
dase treatment, including factors I, VII, IX, and XII, plasminogen,
!brinogen, protein C, and protein S (Fig. S6). Absence of altered
coagulation factor abundance and activity did not however in-
dicate the absence of glycoprotein desialylation. Neuraminidase
doses that reduced platelet levels in circulation similar to that
observed after SPN infection also diminished sialic acid abun-
dance on all glycoproteins analyzed, including those that were un-
altered, indicating selectivity of the AMR for a subset of endo-
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Fig. 4. Coagulopathy and host protection after
anti-CD41 treatment and platelet depletion during
SPN sepsis. (A) Platelet abundance in circulation 2 h
after i.v. injection of anti-CD41 antibody or poly-
clonal IgG at indicated doses. (B) Platelet abundance
in circulation at indicated times after a single i.v.
injection (0.5 mg/kg) of either anti-CD41 or IgG. (C)
ECA and RCA-I lectin binding at the platelet surface
2 h after i.v. injection (0.5 mg/kg) of either anti-CD41
or IgG. (D) Bleeding times after i.v. injection (0.5 mg/
kg) of either anti-CD41 or IgG. (E) Representative
macroscopic and histopathologic views of liver and
spleen 48 h after SPN infection. Fibrin deposition
and empty blood vessels are marked (open arrows).
Blood vessels containing red blood cells are also
denoted (closed arrows). Areas of pyknotic bodies
indicating cell death are marked (asterisks). Fibrin
clots, pyknotic bodies, and splenic hemorrhage were
quanti"ed. (F) Serum alanine aminotransferase ac-
tivity. (G) Survival among mice receiving 0.5 mg/kg
of either anti-CD41 or IgG 8 h after i.p. injection of
SPN isolate D39 (104 cfu). At least 12 age-matched
mice of each genotype were analyzed in B–D from
multiple independent experiments. In G, more than
40 mice of each genotype receiving each treatment
were analyzed in multiple independent experiments.
Findings shown are representative of results obtained
using anti-CD41 and IgG in either WT or AMR-de"cient
mice. ***P < 0.001.
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sepsis (6) (Fig. 7). Endogenous glycoproteins modulated by
the AMR in the physiological context of pneumococcal sepsis
include those with the largest numbers of potential N-glyco-
sylation sites encoded in their primary peptide sequences
(Table S4).
Discussion
The protective role of the host AMR is activated in response
to increased neuraminidase activity in the bloodstream during
sepsis. This is achieved in large part by neuraminidase-dependent
unmasking of cryptic AMR ligands existing on platelets and a
subset of prothrombotic blood coagulation factors. The endo-
cytic AMR reduces the abundance of these desialylated pro-
thrombotic components in producing a hypocoagulative state
that lessens the potential for the onset of disseminated in-
travascular coagulation. Platelets and prothrombotic blood co-
agulation factors can play harmful roles in sepsis when they fuel
pathogen-driven coagulopathy that results in thromboembolic
tissue damage, often with a fatal outcome. Aberrations in
platelet activity may further complicate sepsis by binding and
disseminating bacteria throughout the bloodstream (16, 17) or
by contributing to granzyme B-mediated killing of splenocytes
(18). Regulation of glycoprotein homeostasis by the AMR has
been imperceptible to multiple studies of genomic variation and
transcriptional outputs, re"ecting posttranslational and en-
zymatic processes that modulate metabolism and which are in-
creasingly linked to the origins of common diseases and syndromes
(19–22).
Endogenous glycoproteins bearing AMR ligands have been
dif!cult to identify. Previous studies have included exoge-
nously administered glycoproteins of multiple species often
derived from heterologous cell expression systems and were
used in isolation at various concentrations in circulation. The
potential for ligand selectivity of the homomeric and hetero-
meric AMR complex in determining the relative binding and
clearance rates among endogenous glycoproteins also remains to
be fully studied. Given these complications, it has not been
possible to identify and compare endogenous AMR ligands
produced in a physiological context, as in the course of sepsis.
In comparisons among multiple glycoproteins, we !nd that those
modulated by the AMR and neuraminidase activity have the
largest number of N-glycan sequons in their peptide sequences.
Not all such sequons are necessarily modi!ed with N-glycans;
nevertheless, these !ndings suggest an evolutionary mechanism
that may render a protein responsive to AMR clearance and
further provides an experimental framework to determine struc-
tural features of endogenous AMR ligands that may involve
glycan density in combination with glycoprotein sequence and
structure.
AMR function protects a large fraction of septic animals from
excessive tissue damage and death and appears to be required for
host survival of severe sepsis caused by SPN. This SPN pathogen–






















































































































































































































Fig. 5. (A–D) Treatment with neuraminidase (NA), but not anti-CD41 anti-
body, induces a hypocoagulative state in blood plasma. aPTT and partial
thrombin (PT) time were determined in plasma after either in vivo or in vitro
treatments with neuraminidase or anti-CD41 in parallel comparisons with





















































































































































































































































































































Fig. 6. Blood coagulation factor abundance or activity after (A) i.v. neur-
aminidase (NA) treatment in the presence or absence of AMR function in
mice, and (B) in vitro neuraminidase treatment of human blood plasma.
Wild-type or AMR-de"cient mice were bled 2 h after i.v. treatment with
either AUS NA (5 U/kg) or PBS. Plasma was isolated for measurements of
the abundance or activity of speci"c blood coagulation factors, as previously
described (24, 25). Measurements of glycoprotein abundance were obtained
with anti-factor antibodies. Factor-speci"c enzyme activities were measured
where indicated.











evolution, providing a selective pressure favoring the endocytic
AMR response to counteract pathogen perturbation of the host
coagulation system. The AMR is, however, unable to rescue all
infected animals owing to multiple pathogenic processes that are
ongoing, including cytokine storm that can lead to lethality (23).
When the AMR response is inadequate and as pathogen load
increases, thrombosis continues, and platelets may be further
consumed to less than 10% of normal levels in fulminant dis-
seminated intravascular coagulation when hemorrhage itself
becomes life threatening. It will be of interest to determine
whether i.v. neuraminidase treatment is similarly therapeutic
in sepsis caused by pathogens that lack an encoded neur-
aminidase. The !nding that the “natural” process of AMR
activation in pneumococcal sepsis is not optimal and can be
improved upon re"ects a biological response that has evolved
to preserve species if not all individuals. Such protective
mechanisms may be required for species survival, but may
rarely if ever become optimized by natural selection. The
targeted i.v. administration of neuraminidase during sepsis
merits further exploration as a method to rapidly activate and
augment the life-protective function of the host AMR.
Materials and Methods
Detailed methods, including descriptions of all reagents, are included in SI
Materials and Methods. Data are presented as means ± SEM unless otherwise
indicated. We used the Student unpaired t test, as well as Kaplan-Meier
analyses of survival curves, with Prism software (GraphPad). Multiple-analyte
sera data were compared by two-way ANOVA and t tests. P values of less than
0.05 were considered signi"cant. Statistical signi"cance is presented through-
out as ***P < 0.001, **P < 0.01, or *P < 0.05.
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*** Fig. 7. Blood coagulation factor abundance and
desialylation after i.v. neuraminidase (NA) treat-
ment. Coagulation factor protein abundance mea-
sured by antibodies was further analyzed by ECA
and RCA-I lectins to detect exposed galactose fol-
lowing i.v. treatment with either AUS NA (5 U/kg) or
PBS. Ratios of exposed galactose per unit of protein
antigen were calculated as indicated and as pre-
viously described (25).
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Materials and Methods
Animals. Animal use was limited to adult laboratory mice of the
C57BL/6Hsd strain. All procedures were approved by Institu-
tional Animal Care and Use Committees of the University of
California Santa Barbara and the Sanford-Burnham Medical
Research Institute. Mice were provided sterile pellet food and
water ad libitum. Littermates and related cohorts aged 8–16 wk
were used for experimentation. Mice lacking a functional gene
encoding GPIb! (1) were kindly provided by Zaverio Ruggeri
(The Scripps Research Institute, La Jolla, CA). Mice bearing null
mutations in the genes encoding Asgr1 or Asgr2 have been pre-
viously described (2, 3). All alleles were maintained through at
least eight generations of meiotic recombination in the C57BL/
6NHsd background. All animals were provided sterile pellet food
and water ad libitum. Littermates and related cohorts aged 8–16 wk
were used for experimentation.
Human Subjects. The Institutional Review Board of the Cottage
Health System approved experiments to acquire anonymous
human blood samples for analysis upon informed consent of healthy
volunteers.
Reagents. Chemicals, biologics, and other reagents used included
N-hydroxysuccinimidobiotin (Pierce), paraformaldehyde (Elec-
tron Microscopy Sciences), biotin and FITC-conjugated lectins
including Erythrina cristagalli lectin (ECA) and Ricinus communis-1
agglutinin (RCA-I) (Vector Laboratories), CellTracker Orange
(Molecular Probes), alkaline phosphatase (Sigma), streptavidin-
alkaline phosphatase (BD Pharmingen), Todd-Hewitt broth
(Teknova), RBC lysis buffer (eBioscience), BSA (Jackson
Immunoresearch), serum-separator, and EDTA-Vacutainer
tubes (Becton Dickinson). Enzymes used were Clostridium
histolyticum collagenase (Sigma-Aldrich), Streptococcus pneu-
moniae (SPN) NanA neuraminidase (Seikagaku/Northstar Bio-
products), Vibrio cholerae (VC) neuraminidase (Roche Applied
Science), or Arthrobacter ureafaciens (AUS) neuraminidase (EY
Laboratories). Antibodies included FITC or DyLight649-conju-
gated rat antibodies that bind to CD42a (GPIX, clone Xia.B4),
CD42b (GP1b!, clone Xia.G5), and CD42c (GPIb", clone Xia.
C3) (Emfret Analytics), FITC- or Phycoerythrin (PE)-conju-
gated antibodies to CD41 (MWReg30) and a polyclonal IgG
control (BD Pharmingen), FITC- or APC-conjugated anti-CD61
(2C9.G3), anti-TER119, and all isotype controls (eBiosciences),
von Willebrand Factor (DAKO), antithrombin, coagulation fac-
tors I, II, and X (Hematologic Technologies), and PE-conjugated
anti-Gr1 (clone RB6-8C5) and anti-CD3 (2C11) (eBioscience).
Bleeding Times. Mice were anesthetized and restricted horizon-
tally. The tail was severed 2 mm from the tip (or additional 1 mm
for subsequent time points) with a razor blade and immersed
vertically 1 cm below the surface of 37 °C saline. Time until
bleeding stopped was recorded. Cauterization was not required.
Coagulation and Hematology.Blood used in coagulation assays was
collected by cardiac puncture. Citrated platelet-poor plasma was
prepared from citrated blood by centrifugation at 22 °C. Plasma
samples were aliquoted and frozen at !80 °C within 4 h of blood
collection. Hematology assessment, blood coagulation time as-
says, platelet counts, and blood coagulation factor assays were
performed as previously described (4–6). Platelets were identi-
!ed using "ow cytometry with either anti-CD41 or anti-CD61
antibodies.
Blood Chemistry and Cytokine Measurements. Blood was collected
from the retroorbital sinus while the mouse was kept under
general (inhalant) anesthesia. Blood was collected into Micro-
tainer Serum Separator Tubes (BD) with no anticoagulant and
allowed to clot for 30 min at room temperature. Sera collected
after centrifugation at 13,000 rpm for 10 min. For blood chem-
istry, a VetScan Comprehensive Diagnostic Pro!le reagent rotor
was used with the VetScan Chemistry Analyzer according to the
manufacturers’ instructions.
Neuraminidase and Anti-CD41 Treatment. For in vitro treatment,
isolated whole blood was incubated with neuraminidase doses
as indicated in the text, ranging from 0.001 to 0.3 U/mL for 2 h at
37 °C before analysis. For in vivo treatment, neuraminidase or
antibody was i.v. injected into the retroorbital sinus or the tail vein.
Neuraminidase doses ranging from 0.25 to 50 U/kg in 100 #L
diluted with PBS were i.v. injected (via retroorbital sinus). Anti-
CD41 or polyclonal IgG control (0.5 mg/kg) were diluted up to
100 #L in PBS and delivered i.v. into the retroorbital plexus. Serial
samples were taken by retroorbital sinus bleeds after injection.
Each mouse was bled up to 3 time points for analyses of coagulation
factor levels or activity.
Mouse Platelet Isolation, Survival, and Fate. Whole blood was in-
cubated in vitro with indicated neuraminidase at speci!ed dose
for 2 h at 37 °C. For the !nal 30 min, CellTracker red was added
to 2- #M !nal concentration. Platelet-rich plasma was prepared
by centrifugation at 268 ! g for 8 min. Platelets were separated
from platelet-rich plasma by centrifugation at 834 ! g for 5 min
and washed twice in Tyrode’s buffer (137 mmol/L NaCl, 2.8
mmol/L KCl, 1 mmol/L MgCl2, and 10 mmol/L Hepes, pH 7.4)
to remove excess CellTracker dye. Platelet-rich plasma from
donor mice were used in in vitro experiments or infused into
recipient mice of indicated genotypes via retroorbital sinus in
a maximum volume of 200 #L. Blood samples were obtained at
indicated time points to evaluate circulatory half-life of donor
platelets in recipient mice by "ow cytometry. Platelets were
identi!ed by forward- and side-scatter pro!les and con!rmed
by anti-CD41 antibody binding. The relative proportion of
CellTracker-loaded infused donor platelets remaining in circu-
lation (visible in phycoerythrin detection channel) was calculated
as a percentage of that measured at the !rst time point collected
1 to 2 min after transfusion.
SPN Infection.Wild-type (SPN) serotype 2 isolate D39 was used
throughout the study as previously described (3). All bacte-
rial infections were administered by i.p. injection at cfu doses
indicated.
Histology. Tissues were !xed in 10% (vol/vol) buffered formalin,
trimmed, processed, embedded in paraf!n, sectioned at a width
of 5 #m, histochemically stained, and visualized by light microscopy
at magni!cations indicated and as previously described (3).
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Fig. S1. Dose–response of microbial neuraminidases in platelet desialylation and the induction of thrombocytopenia. Circulating platelet sialylation and
abundance in WT mice were measured by "ow cytometry 2 h after i.v. administration of indicated doses of neuraminidase (NA) obtained from (A) SPN, (B) AUS,
and (C) VC. Platelets were identi!ed with anti-CD41 antibody. Red blood cells were identi!ed with Ter-119 antibody. Exposure of galactose after desialylation
was simultaneously determined with ECA and RCA-I lectins.















































































































Fig. S2. Hematological measurements after i.v. neuraminidase treatment. Wild-type mice were bled 2 h after i.v. treatment with neuraminidase (NA) or PBS
before measuring (A) red blood cell parameters and (B) nucleated blood cell measurements. Desialylation of blood cells representing neutrophils (Gr1+), T cells
(CD3+), and B cells (B220+) were determined by "ow cytometry with measurements of ECA and RCA-I lectin binding. Similar results were observed at 24 h after
treatment. HCT, hematocrit; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; RDW,
red blood cell distribution width.
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Fig. S3. In"ammation marker abundance in the blood after neuraminidase (NA) treatment. Abundance of indicated cytokines in blood sera determined using
ELISA at multiple time points after i.v. administration of PBS or neuraminidase to WT mice. RANTES (regulated on activation, normal T cell expressed and
secreted) is also Chemokine ligand 5 (CCL5).
























































Fig. S4. Desialylation and glycoprotein abundance at the surface of platelets after neuraminidase (NA) treatment. (A) Platelet desialylation and (B) platelet
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Fig. S5. Survival of mice administered i.v. neuraminidase at different times after SPN infection. (A) WT mice were infected with a lethal dose (2 ! 105 cfu) of
SPN by i.p. injection and were administered PBS or neuraminidase i.v. 24 h after infection. In parallel studies, (B) WT mice were infected with an LD50 dose (1 !
103 cfu) of SPN by i.p. injection and were administered PBS or neuraminidase i.v. 48 h after infection. White squares, PBS treatments; black squares, neur-
aminidase treatments.
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Fig. S6. Abundance or activity of blood coagulation factors by i.v. neuraminidase treatment. WT and Ashwell-Morell receptor (AMR)-de!cient mice were bled
2 h after i.v. treatment with either neuraminidase (NA) or PBS. Plasma was isolated for measurements of blood coagulation factor abundance and activity as
previously described (5, 6).
Grewal et al. www.pnas.org/cgi/content/short/1313905110 6 of 8
Table S1. Blood chemistry in WT mice after neuraminidase administration in vivo and in vitro
Analyte In vitro PBS In vitro NA In vivo PBS In vivo SPN NA In vivo AUS NA In vivo VC NA
Albumin (g/dL) 2.9 ± 0.3 2.9 ± 0.4 3.6 ± 0.2 4.2 ± 0 3.3 ± 0.1 3 ± 0.2
Alanine aminotransferase (U/L) 47.3 ± 11 48.5 ± 10.2 43.6 ± 9.5 33.5 ± 13 43.8 ± 3.5 39 ± 6.5
Amylase (U/L) 937 ± 64 921 ± 53 795.5 ± 135.3 791.5 ± 168.5 784.0 ± 145.5 850 ± 199
Total bilirubin (mg/dL) 0.2 ± 0 0.2 ± 0 0.2 ± 0.0 0.3 ± 0 0.2 ± 0.0 0.2 ± 0
Total nitrogen (mg/dL) 21 ± 1 20.3 ± 1.1 10.5 ± 2.1 24.5 ± 1 18.3 ± 6.8 15.5 ± 1.5
Calcium (mg/dL) 8.9 ± 0.1 8.7 ± 0.2 9.0 ± 0.1 9.1 ± 0 9.3 ± 0.1 9.56 ± 0.1
Phosphorus (mg/dL) 9 ± 0.4 11.2 ± 1.4 9.7 ± 0.5 8.2 ± 0.6 8.0 ± 1.4 7.8 ± 0.2
Creatinine (mg/dL) 0.2 ± 0 0.2 ± 0 0.2 ± 0 0.2 ± 0 0.2 ± 0.0 0.2 ± 0
Glucose (mg/dL) 191 ± 5 189.3 ± 2.6 169.5 ± 9 175.5 ± 9.5 179.0 ± 5.1 173 ± 2
Sodium (mmol/L) 151 ± 2 153 ± 0.6 151.5 ± 1.4 151 ± 1 151.1 ± 1.8 154.5 ± 0.5
Potassium (mmol/L) 4.7 ± 0.5 5.6 ± 0.5 5.2 ± 0.3 4.7 ± 0.5 5.7 ± 0.5 4.8 ± 0.2
Total protein (g/dL) 4.7 ± 0.2 4.6 ± 0.2 4.9 ± 0.2 5.1 ± 0.2 4.5 ± 0.1 4.6 ± 0.1
Globulin (g/dL) 1.7 ± 0.2 1.7 ± 0.2 1.5 ± 0.2 0.9 ± 0.2 1.6 ± 0.3 1.5 ± 0.1
In vivo analyses were accomplished among sera isolated 2 h after i.v. administeration of PBS or neuraminidase (NA). In vitro analyses
were accomplished on sera prepared 30 min after addition of PBS or neuraminidase to isolated whole blood.



























Albumin (g/dL) 3.7 ± 0.1 2.7 ± 0.2 1.5 ± 0.2 3.6 ± 0.2 3.2 ± 0.4 2.3 ± 0.2 3.6 ± 0.1 2.5 ± 0.2 2.0 ± 0.2
Amylase (U/L) 815 ± 57.2 1768 ± 331 2109 ± 459 739 ± 75.9 1128 ± 51 1367 ± 185 705 ± 49.3 1016 ± 170 1467 ± 309
Total bilirubin (mg/dL) 0.2 ± 0 0.2 ± 0.0 0.25 ± 0.02 0.2 ± 0 0.2 ± 0.0 0.25 ± 0.02 0.2 ± 0 0.3 ± 0.1 0.3 ± 0.04
Calcium (mg/dL) 9.0 ± 0.1 9.9 ± 0.2 8.0 ± 0.4 9.7 ± 0.3 9.0 ± 0.5 8.3 ± 0.4 9.4 ± 0.1 10.1 ± 0.1 8.5 ± 0.3
Phosphorus (mg/dL) 7.6 ± 0.5 7.6 ± 0.8 12.2 ± 1.7 9.7 ± 0.7 9.6 ± 0.4 15.6 ± 1.3 8.8 ± 0.4 9.3 ± 1.1 12.4 ± 2.6
Creatinine (mg/dL) 0.2 ± 0.01 0.2 ± 0.01 0.23 ± 0.02 0.2 ± 0 0.22 ± 0.02 0.28 ± 0.04 0.2 ± 0 0.2 ± 0 0.23 ± 0.03
Glucose (mg/dL) 156.9 ± 11.8 147.0 ± 2.6 167.0 ± 15.7 142.9 ± 11.9 144.7 ± 12.9 147.0 ± 14.2 163.0 ± 13 152.3 ± 6.7 146.5 ± 14.9
Sodium (mmol/L) 149.8 ± 1.1 152.3 ± 1.2 149.5 ± 0.7 154.4 ± 1.3 149.3 ± 1.2 152.7 ± 1.9 147.9 ± 1.2 145.0 ± 2.3 147.3 ± 2.3
Potassium (mmol/L) 5.0 ± 0.3 5.5 ± 0.3 5.7 ± 0.5 5.1 ± 0.1 5.4 ± 0.4 6.1 ± 0.6 5.2 ± 0.2 5.2 ± 0.2 4.9 ± 0.3
Total protein (g/dL) 4.7 ± 0.1 5.5 ± 0.1 3.6 ± 0.2 5.2 ± 0.3 5.1 ± 0.2 4.8 ± 0.2 4.9 ± 0.1 4.6 ± 0.3 4.2 ± 0.2
Globulin (g/dL) 1.2 ± 0.1 2.7 ± 0.2 2.0 ± 0.1 1.6 ± 0.1 2.8 ± 0.1 2.4 ± 0.2 1.3 ± 0.1 2.1 ± 0.3 2.3 ± 0.3
Measurements were completed on sera prepared from untreated or SPN-infected mice of the indicated genotypes 24 h after infection and 16 h after i.v.
administration of PBS or neuraminidase (NA).


















Albumin (g/dL) 3.6 ± 0.2 2.5 ± 0.3 2.2 ± 0.2 3.6 ± 0.1 2.6 ± 0.2 2.7 ± 0.2
Amylase (U/L) 739 ± 75.9 1012 ± 148 948 ± 111.8 705 ± 49.3 1528 ± 252 1071 ± 154.8
Total bilirubin (mg/dL) 0.2 ± 0 0.2 ± 0.0 0.23 ± 0 0.2 ± 0 0.5 ± 0.2 0.22 ± 0.02
Calcium (mg/dL) 9.7 ± 0.3 8.6 ± 0.7 9.9 ± 0.2 9.4 ± 0.1 9.2 ± 0.4 9.2 ± 0.3
Phosphorus (mg/dL) 9.7 ± 0.7 9.5 ± 0.8 10.1 ± 0.9 8.8 ± 0.4 12.3 ± 2.5 11.5 ± 2.3
Creatinine (mg/dL) 0.2 ± 0 0.23 ± 0.03 0.25 ± 0.1 0.2 ± 0 0.2 ± 0 0.24 ± 0.04
Glucose (mg/dL) 142.9 ± 11.9 138.3 ± 5.3 168.5 ± 25.4 163.0 ± 13 134.7 ± 16 149 ± 10.8
Sodium (mmol/L) 154.4 ± 1.3 152.3 ± 1.9 158 ± 2.3 147.9 ± 1.2 151.3 ± 1.9 146.8 ± 2.1
Potassium (mmol/L) 5.1 ± 0.1 5.6 ± 0.3 6.1 ± 0.4 5.2 ± 0.2 5.9 ± 0.5 5.8 ± 0.6
Total protein (g/dL) 5.2 ± 0.3 4.7 ± 0.3 5.0 ± 0.2 4.9 ± 0.1 4.6 ± 0.2 4.9 ± 0.2
Globulin (g/dL) 1.6 ± 0.1 2.5 ± 0.2 2.8 ± 0.1 1.3 ± 0.1 2.2 ± 0.3 2.3 ± 0.2
Measurements were completed on sera prepared from untreated or SPN-infected mice 24 h after infection and 16 h after i.v. treatment with anti-CD41 or
polyclonal IgG antibodies.
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Table S4. N-glycosylation consensus sites in human and mouse protein orthologs
Glycoprotein
Homo sapiens Mus musculus
Total amino acids No. of sites N-site position Total amino acids No. of sites N-site position
I (!-Fibrinogen) 866 3 419; 686; 831 789 2 609; 754
I ("-Fibrinogen) 491 1 394 481 1 384
I ($-Fibrinogen) 453 1 78 436 1 77
II (Prothrombin) 622 4 121; 143; 205; 416 618 5 122; 144; 207; 413; 553
V 2,224 37 51; 55; 239; 297; 382; 460;
468; 554; 667; 741; 752;
760; 776; 782; 821; 938;
977; 1074; 1083; 1103;
1106; 1203; 1221; 1257;
1266; 1293; 1311; 1338;
1347; 1374; 1383; 1479;
1499; 1559; 1703; 2010;
2209
2183 26 176; 238; 296; 381; 459;
552; 740; 751; 759; 775;
820; 841; 959; 972; 1038;
1049; 1058; 1067; 1088;
1438; 1459; 1460; 1519;
1663; 1811; 2168
VII 466 2 205; 382 446 2 186; 244
VIII 2,351 25 60; 258; 601; 776; 803;
847; 919; 962; 982; 1020;
1024; 1074; 1085; 1204;
1274; 1278; 1301; 1319;
1403; 1431; 1461; 1531;
1704; 1829; 2137
2319 26 61; 233; 259; 423; 601; 880;
958; 1015; 1022; 1026;
1044; 1076; 1087; 1136;
1161; 1192; 1255; 1268;
1273; 1274; 1302; 1316;
1340; 1378; 1797; 2105
IX 461 2 203; 213 471 4 36; 204; 223; 316
X 488 2 221; 231 481 2 187; 218
XI 625 5 90; 126; 353; 450; 491 624 6 90; 126; 297; 355; 449; 490
XII 615 2 249; 433 597 4 249; 271; 324; 415
vWF 2,813 16 99; 156; 211; 666; 857;
1231; 1515; 1574; 2223;
2290; 2357; 2400; 2546;
2585; 2635; 2790
2813 15 99; 156; 666; 857; 1005;
1231; 1515; 1574; 2223;
2290; 2400; 2546; 2585;
2790; 2810
Antithrombin 464 4 128; 167; 187; 224 465 4 129; 168; 188; 225
Protein C 461 3 139; 290; 355 460 3 214; 290; 354
Protein S 676 3 499; 509; 530 675 2 499; 509
Plasminogen 810 1 307 812 2 136; 307
!2 Antiplasmin 491 4 126; 295; 309; 316 491 4 126; 295; 309; 316
Numbers and positions of N-glycosylation consensus sites in each ortholog with site positions indicated relative to methionine at position 1. N-glycosylation
consensus sites are de!ned as Asn-Xaa-Ser/Thr (NXS/T), where Xaa is any amino acid except proline. Numbers in bold indicate N-glycosylation sequons/positions
conserved between human and mouse orthologs. Protein sequences were obtained from the UniProt Knowledgebase (www.uniprot.org) and analyzed using
NetNGlyc (http://www.cbs.dtu.dk/).
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